Also known as: Salmeterol Xinafoate Salt; Serevent Diskus
Salmeterol Xinafoate is the xinafoate salt form of Salmeterol, exhibiting improved stability and physicochemical properties suitable for dry powder inhaler formulations. Mediocon Inc supplies pharmaceutical-grade Salmeterol Xinafoate conforming to IP / BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.
The xinafoate salt provides enhanced powder flow properties essential for DPI manufacturing. It is the commercially dominant salt form found in widely used respiratory products.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2030 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Salmeterol Xinafoate (CAS 80214-83-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Salmeterol Xinafoate is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance